Imagion Biosystems receives AU$2.5 million in R&D tax incentives

ASX Announcement:

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it has received its 2021 R&D tax incentive claim of $2,500,966 from the Australian Taxation Office. This is materially similar to the $2,612,159 received in respect of the 2020 claim and reflects a similar level of R&D spend in 2021.

 

About Imagion Biosystems:

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

Link to the ASX announcement HERE.

 


Questions about this announcement or other investor-related inquiries? Please email our investor relations department at: investor@imagionbio.com.